RxDoctor Payments Data

Munther Homoud, MD

Cardiovascular Disease · Boston, MANPI 1225144058

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (31.6%), travel and lodging and consulting fees — rather than concentrated in one kind of arrangement. Abbott accounts for 82.2% of it on its own, with 8 other manufacturers making up the rest. Reporting peaked in 2021 at $4,087 and has fallen 83.6% since, to $670 in 2025.

$12,763in general payments, 2019–2025

Across 72 payments — averaging $177.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$10K
  • Medtronic$1K
  • Biosense Webster, Inc.$216
  • Biotronik Inc.$215
  • Impulse Dynamics (USA) Inc.$169
  • Atricure, Inc.$156
  • plus $127 from 3 others
$13,900in research payments, 2019–2025

Across 8 payments — averaging $1737.50 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Abbott$14K

What the payments were for

  • Consulting fees$3,40027%
  • Speaking & faculty fees$4,03832%
  • Travel & lodging$3,40827%
  • Food & beverage$1,91715%
  • Education$10%

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,763 in reported general payments places this provider in the 75th percentile of 750 cardiovascular disease providers in Massachusetts.

See all cardiovascular disease providers in Massachusetts →

Medicare billing

Part B allowed, 2024
$167,828
Medicare patients
849
Services billed
1,841

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban40$53,567
XareltoRivaroxaban13$15,112
Metoprolol Succinate35$561
Amiodarone Hcl22$239
Metoprolol Tartrate11$81

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$30$53,56740 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 750 cardiovascular disease providers in Massachusetts.

Other cardiovascular disease in Boston

See the full list for Massachusetts →

Where these figures come from

Is this you, or does something look wrong? →